Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Dried Blood Spots Detect Clonal B-Cell Populations

By LabMedica International staff writers
Posted on 14 Oct 2013
The reliability of lymphoma diagnoses is strikingly different between developed and developing countries due to lack of access to advanced techniques.

Molecular methods are important tools for diagnosis and monitoring of many lymphoproliferative disorders, and new application of dried blood spots (DBS) for detecting clonal B-cell populations in peripheral blood (PB) has been proposed. More...


Scientists at the University of Padua (Italy) obtained blood samples from six patients with B-cell chronic lymphocytic leukemia (B-CLL) and five consenting healthy volunteer donors. Dried blood spot samples from African children with non-Hodgkin's lymphoma (NHL) were also analyzed.

Genomic DNA was isolated with the automated MagNA Pure Compact instrument (Roche Applied Science, Indianapolis, IN, USA) The extracted DNA samples were tested for B-cell immunoglobulin heavy chain (IGH) clonality with the IGH gene clonality assay (Invivoscribe Technologies; San Diego, CA, USA), containing BIOMED-2 primers, positive and negative controls.

The Namalwa B-cell line was used to establish that the assay was sensitive enough to detect 200 clonal cells in the analyzed sample. Very similar clonal results were obtained between DNA from DBS and fresh whole blood from patients with B-cell chronic lymphocytic leukemia. B-cell clonality can also be detected in DBS from African children with Epstein-Barr Virus (EBV)-associated diseases.

DBS cards are a feasible alternative for diagnosing and monitoring various diseases in the developing world. DBS sampling was also suitable to verify the presence of B-cell clonal populations circulating in the blood by immunoglobulin gene rearrangement analysis, with a view to offering molecular evaluation to the diagnosis and monitoring of lymphoproliferative diseases in resource-limited settings.

A diagnosis of leukemia is not usually problematic as immunophenotyping and cytogenetic analysis and histochemical staining can establish diagnosis in virtually all leukemia cases. However, a diagnosis of leukemia may sometimes be more complicated, and molecular clonality evaluation is thought to produce valuable additional information. DBS cards may be useful tools when the molecular analyses complementary to histomorphological/immunophenotypic evaluation are not available. The study was published in the October 2013 issue of the journal Leukemia Research.

Related Links:
University of Padua
Roche Applied Science
Invivoscribe Technologies



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Automated Urinalysis Solution
UN-9000
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.